74 filings
8-K
FSTX
F-star Therapeutics Inc
9 Mar 23
Completion of Acquisition or Disposition of Assets
8:27am
8-K
FSTX
F-star Therapeutics Inc
7 Mar 23
F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma
9:08am
8-K
FSTX
F-star Therapeutics Inc
6 Mar 23
Entry into a Material Definitive Agreement
9:31am
8-K
FSTX
F-star Therapeutics Inc
23 Feb 23
Entry into a Material Definitive Agreement
8:45am
8-K
FSTX
F-star Therapeutics Inc
9 Feb 23
Entry into a Material Definitive Agreement
9:01am
8-K
7inkb
1 Feb 23
Entry into a Material Definitive Agreement
8:44am
8-K
r5jer51m 95p
30 Dec 22
Entry into a Material Definitive Agreement
8:37am
8-K
0wg0n
29 Dec 22
Other Events
9:02am
8-K
cj0fxbx7
21 Dec 22
Entry into a Material Definitive Agreement
6:08am
8-K
bwoglnrb6go
19 Dec 22
Entry into a Material Definitive Agreement
11:57am
8-K
lu3pvk7ujqiq5
21 Nov 22
Entry into a Material Definitive Agreement
6:36am
8-K
yshb3 ymx
1 Nov 22
Other Events
8:58am
8-K
rk6i3c
11 Aug 22
F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
9:20am
8-K
1y3h6vg8fsiv rr8
23 Jun 22
Invox Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs
9:25am
8-K
ru5 q2iam9
16 Jun 22
Submission of Matters to a Vote of Security Holders
5:18pm
8-K
kphxgef
10 May 22
F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
8:22am
8-K
h96u 5jacqz36cl91pi
14 Mar 22
F-star Therapeutics Reports Full-Year 2021 Financial Results and Provides Corporate Update
8:09am
8-K
gc5r1lmnl3l5r8dw
6 Jan 22
F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration
8:16am
8-K
ijx00y5a59v
12 Nov 21
F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference
8:34am
8-K
ya48ampwq
10 Nov 21
F-star Therapeutics Reports Third Quarter 2021 Financial Results
8:30am